Literature DB >> 18344458

Spinocerebellar ataxia type 2 presenting with cognitive regression in childhood.

Melissa B Ramocki1, Lynn Chapieski, Ryan O McDonald, Fabio Fernandez, Amy D Malphrus.   

Abstract

Spinocerebellar ataxia type 2 typically presents in adulthood with progressive ataxia, dysarthria, tremor, and slow saccadic eye movements. Childhood-onset spinocerebellar ataxia type 2 is rare, and only the infantile-onset form has been well characterized clinically. This article describes a girl who met all developmental milestones until age 3(1/2) years, when she experienced cognitive regression that preceded motor regression by 6 months. A diagnosis of spinocerebellar ataxia type 2 was delayed until she presented to the emergency department at age 7 years. This report documents the results of her neuropsychologic evaluation at both time points. This case broadens the spectrum of spinocerebellar ataxia type 2 presentation in childhood, highlights the importance of considering a spinocerebellar ataxia in a child who presents with cognitive regression only, and extends currently available clinical information to help clinicians discuss the prognosis in childhood spinocerebellar ataxia type 2.

Entities:  

Mesh:

Year:  2008        PMID: 18344458      PMCID: PMC2692330          DOI: 10.1177/0883073808315622

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  16 in total

1.  The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia.

Authors:  D H Geschwind; S Perlman; C P Figueroa; L J Treiman; S M Pulst
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

2.  SCA2 trinucleotide expansion in German SCA patients.

Authors:  O Riess; F A Laccone; S Gispert; L Schöls; C Zühlke; A M Vieira-Saecker; S Herlt; K Wessel; J T Epplen; B H Weber; F Kreuz; S Chahrokh-Zadeh; A Meindl; A Lunkes; J Aguiar; M Macek; A Krebsová; M Macek; K Bürk; S Tinschert; I Schreyer; S M Pulst; G Auburger
Journal:  Neurogenetics       Date:  1997-05       Impact factor: 2.660

3.  Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguín, Cuba.

Authors:  G Orozco Diaz; A Nodarse Fleites; R Cordovés Sagaz; G Auburger
Journal:  Neurology       Date:  1990-09       Impact factor: 9.910

4.  Dominantly inherited olivopontocerebellar atrophy from eastern Cuba. Clinical, neuropathological, and biochemical findings.

Authors:  G Orozco; R Estrada; T L Perry; J Araña; R Fernandez; A Gonzalez-Quevedo; J Galarraga; S Hansen
Journal:  J Neurol Sci       Date:  1989-10       Impact factor: 3.181

5.  Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.

Authors:  Robert J Ferrante; James K Kubilus; Junghee Lee; Hoon Ryu; Ayshe Beesen; Birgit Zucker; Karen Smith; Neil W Kowall; Rajiv R Ratan; Ruth Luthi-Carter; Steven M Hersch
Journal:  J Neurosci       Date:  2003-10-15       Impact factor: 6.167

6.  Spinocerebellar ataxia type 2 (SCA2) presenting with ophthalmoplegia and developmental delay in infancy.

Authors:  Paolo Moretti; Maria Blazo; Leonardo Garcia; Dawna Armstrong; Richard Alan Lewis; Benjamin Roa; Fernando Scaglia
Journal:  Am J Med Genet A       Date:  2004-02-01       Impact factor: 2.802

7.  Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1.

Authors:  S Gispert; R Twells; G Orozco; A Brice; J Weber; L Heredero; K Scheufler; B Riley; R Allotey; C Nothers
Journal:  Nat Genet       Date:  1993-07       Impact factor: 38.330

8.  SCA2 is not a major locus for ADCA type I in French families.

Authors:  G Cancel; G Stevanin; A Dürr; H Chneiweiss; C Penet; Y Pothin; Y Agid; A Brice
Journal:  Am J Med Genet       Date:  1995-10-09

9.  Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families.

Authors:  A Dürr; D Smadja; G Cancel; A Lezin; G Stevanin; J Mikol; R Bellance; G G Buisson; H Chneiweiss; J Dellanave
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

10.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Authors:  Emma Hockly; Victoria M Richon; Benjamin Woodman; Donna L Smith; Xianbo Zhou; Eddie Rosa; Kirupa Sathasivam; Shabnam Ghazi-Noori; Amarbirpal Mahal; Philip A S Lowden; Joan S Steffan; J Lawrence Marsh; Leslie M Thompson; Cathryn M Lewis; Paul A Marks; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

View more
  9 in total

1.  Massive expansion of SCA2 with autonomic dysfunction, retinitis pigmentosa, and infantile spasms.

Authors:  A R Paciorkowski; Y Shafrir; J Hrivnak; M C Patterson; M B Tennison; H B Clark; C M Gomez
Journal:  Neurology       Date:  2011-08-31       Impact factor: 9.910

Review 2.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

3.  Infantile childhood onset of spinocerebellar ataxia type 2.

Authors:  Roberto Di Fabio; Filippo Santorelli; Enrico Bertini; Martina Balestri; Laura Cursi; Alessandra Tessa; Francesco Pierelli; Carlo Casali
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

Review 4.  Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches.

Authors:  Luis C Velázquez-Pérez; Roberto Rodríguez-Labrada; Juan Fernandez-Ruiz
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

5.  Next Generation Sequencing of 134 Children with Autism Spectrum Disorder and Regression.

Authors:  Jiani Yin; Chun-An Chun; Nikolay N Zavadenko; Natalia L Pechatnikova; Oxana Yu Naumova; Harsha V Doddapaneni; Jianhong Hu; Donna M Muzny; Christian P Schaaf; Elena L Grigorenko
Journal:  Genes (Basel)       Date:  2020-07-25       Impact factor: 4.096

6.  Finding commonalities in rare diseases through the undiagnosed diseases network.

Authors:  Josephine Yates; Alba Gutiérrez-Sacristán; Vianney Jouhet; Kimberly LeBlanc; Cecilia Esteves; Thomas N DeSain; Nick Benik; Jason Stedman; Nathan Palmer; Guillaume Mellon; Isaac Kohane; Paul Avillach
Journal:  J Am Med Inform Assoc       Date:  2021-07-30       Impact factor: 4.497

7.  Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study.

Authors:  Kristina Ibañez; James Polke; R Tanner Hagelstrom; Egor Dolzhenko; Dorota Pasko; Ellen Rachel Amy Thomas; Louise C Daugherty; Dalia Kasperaviciute; Katherine R Smith; Zandra C Deans; Sue Hill; Tom Fowler; Richard H Scott; John Hardy; Patrick F Chinnery; Henry Houlden; Augusto Rendon; Mark J Caulfield; Michael A Eberle; Ryan J Taft; Arianna Tucci
Journal:  Lancet Neurol       Date:  2022-03       Impact factor: 59.935

Review 8.  Juvenile Huntington's Disease and Other PolyQ Diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic and Proteomic Data.

Authors:  Karolina Świtońska-Kurkowska; Bart Krist; Joanna Delimata; Maciej Figiel
Journal:  Front Cell Dev Biol       Date:  2021-07-01

Review 9.  Cognitive dysfunction in spinocerebellar ataxias.

Authors:  Helio Afonso Ghizoni Teive; Walter Oleschko Arruda
Journal:  Dement Neuropsychol       Date:  2009 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.